Table 1.
Characteristics of patients and control heart donors whose samples were used in this study.
| CCC | NIC | N | |
|---|---|---|---|
| n | 14 | 8 | 6 |
| Age | 47.2 ± 14.6 | 53.3 ± 7.5 | 32.2 ± 12.8 |
| Sex (M/F) | 5/9 | 0/9 | 0/6 |
| EF | 26.50 ± 8.96 | 22.73 ± 6.28 | ND |
| Fibrosis | Moderate to intense | Moderate to intense | 0 |
| LVDD | 71.64 ± 7.48 | 75.86 ± 15.84 | ND |
| Hypertrophy | Yes | Yes | No |
| Myocarditis | Moderate to intense | Absent | 0 |
Age (years); M (male); F (female); CCC (chronic Chagas cardiomyopathy); NIC (noninflammatory cardiomyopathy). Normal heart donors (N) were subject to ventilator and vasoactive drugs and had been under life support for an average of 48 hours. Characterization of the samples as myocarditis, fibrosis, and hypertrophy; reference values for the presence of myocarditis and fibrosis: absent; slight; moderate; intense; hypertrophy: Y (yes), N (no). ND (not done); EF (left ventricular ejection fraction) ≥ 55%; LVDD (left ventricle diastolic diameter); reference value: diameter 39–55 mm.